254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013

Eitemau Tebyg

• In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
  gan: Walkty, A., et al.
  Cyhoeddwyd: (2011)
• 2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017
  gan: Walkty, Andrew, et al.
  Cyhoeddwyd: (2018)
• In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
  gan: Walkty, Andrew, et al.
  Cyhoeddwyd: (2017)
• In Vitro Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012
  gan: Walkty, A., et al.
  Cyhoeddwyd: (2013)
• Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study
  gan: Karlowsky, James A., et al.
  Cyhoeddwyd: (2011)